Market Newsdesk

TORONTO, Sept. 15, 2021 /PRNewswire/ – Hut 8 Mining Corp. (Nasdaq: HUT) (TSX: HUT) (“Hut 8” or the “Company“) today announced the pricing of its previously announced underwritten public offering in the United States and Canada (the “Offering“). 

The Company has agreed to sell to the underwriters (the “Underwriters”) 17,550,000 common shares (the “Common Shares”) at a price of US$8.55 per share resulting in total gross proceeds to the Company of US$150,052,500.

The Offering is expected to close on September 17, 2021 subject to customary closing conditions, including approvals of the NASDAQ Stock Exchange and the Toronto Stock Exchange. 

In addition, the Company has granted the Underwriters an over-allotment option, exercisable for a period of 30 days from the date of the closing of the Offering, to purchase up to 2,632,500 additional Common Shares, representing 15% of the total number of common shares to be sold pursuant to the Offering.

The Company anticipates the net proceeds of the Offering will be used to support the growth of its business including to fund capital investments in digital assets mining equipment to increase mining capacity, for working capital and other general corporate purposes and potentially for strategic partnerships, joint ventures, or acquisitions.

Canaccord Genuity is acting as the Sole Bookrunner for the Offering and Stifel GMP and Craig-Hallum are acting as Co-Managers for the Offering.

In connection with the Offering, the Company filed a preliminary prospectus supplement, and a final prospectus supplement will also be filed, with the U.S. Securities and Exchange Commission as a supplement to the base shelf prospectus included in the Company’s effective registration statement on Form F-10 (SEC File No. 333-254059) under the U.S.-Canada multijurisdictional disclosure system (MJDS).  The Company also filed a preliminary prospectus supplement, and will file a final prospectus supplement, to its base shelf prospectus with the securities regulatory authorities in each of the provinces and territories of Canada.  The Offering will be made in the United States only by means of the registration statement, including the base shelf prospectus and applicable prospectus supplement and in Canada only by means of the base shelf prospectus and applicable prospectus supplement. Such documents contain important information about the Offering. Copies of, the registration statement and the preliminary prospectus supplement can and will be found on EDGAR at www.sec.gov and copies of the base shelf prospectus and the applicable prospectus supplement can and will be found on SEDAR at www.sedar.com. Copies of such documents may also be obtained from any of the following sources: Canaccord Genuity LLC, Attention: Syndicate Department, 99 High Street, 12th Floor, Boston MA 021990, by email at [email protected]; or by contacting the Corporate Secretary of the Company at Suite 500, 24 Duncan Street, Toronto, Ontario, Canada, M5V 2B8, by email at [email protected].

Prospective investors should read the base shelf prospectus and the prospectus supplement as well as the registration statement before making an investment decision.

No securities regulatory authority has either approved or disapproved the contents of this press release. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the common shares in any province, state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such province, state or jurisdiction.

About Hut 8 Mining Corp.

Hut 8 is one of North America’s largest innovation-focused digital asset miners, supporting open and decentralized systems since 2018. Located in energy rich Alberta, Canada, Hut 8 has one of the highest installed capacity rates in the industry and holds more self-mined Bitcoin than any crypto miner or publicly traded company globally. Hut 8 is executing on its commitment to mining and holding Bitcoin and has a diversified business and revenue strategy to grow and protect shareholder value regardless of Bitcoin’s market direction. The Company’s multi-pronged business strategy includes profitable digital asset mining, white-label high-performance compute hosting, as well as yield & income programs leveraging its Bitcoin held in reserve. Having demonstrated rapid growth and a stellar balance sheet, Hut 8 was the first publicly traded miner on the TSX and the first Canadian miner to be listed on The Nasdaq Global Select Market. Hut 8’s team of business building technologists are believers in decentralized systems, stewards of powerful industry-leading solutions, and drivers of innovation in digital asset mining and high-performance computing, with a focus on ESG alignment. Through innovation, imagination, and passion, Hut 8 is helping to define the digital asset revolution to create value and positive impacts for its shareholders and generations to come.

Cautionary Statement Regarding Forward-Looking Statements

This release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. Readers are cautioned that such information may not be appropriate for other purposes. Forward-looking statements and information include, but are not limited to, statements with respect to pricing of the Offering and its completion.

Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by Hut 8 as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to: there being insufficient investor demand for the Offering; economic and market conditions being conducive to the Offering on the timeline currently anticipated or at all; fluctuations in the market price of the Company’s common shares; risks related to the COVID-19 pandemic and its impact on the Company, economic conditions, and global markets; the failure of the Company and/or the underwriters to satisfy closing conditions to the Offering; other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant and those factors described in greater detail in our most recent annual and interim management’s discussion and analysis, and in the “Risk Factors” section of the prospectus supplement dated September 14, 2021 and the Company’s annual information form dated March 25, 2021, which are available at

www.sedar.com

, and should be considered carefully by prospective investors.

If any of these risks or uncertainties materialize, or if the opinions, estimates or assumptions underlying the forward-looking information prove incorrect, actual results or future events might vary materially from those anticipated in the forward-looking information. Although we have attempted to identify important risk factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other risk factors not presently known to us or that we presently believe are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. No forward-looking statement is a guarantee of future results. Accordingly, you should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this press release represents our expectations as of the date specified herein and are subject to change after such date. However, we disclaim any intention or obligation or undertaking to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

All of the forward-looking information contained in this press release is expressly qualified by the foregoing cautionary statements.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hut-8-mining-announces-pricing-of-us150-million-public-offering-301377571.html

SOURCE Hut 8 Mining Corp.

SHANGHAI, Sept. 15, 2021 /PRNewswire/ — Noah Holdings Limited (“Noah” or the “Company”) (NYSE: NOAH), a leading and pioneer wealth management service provider in China offering comprehensive one-stop advisory services on global investment and asset allocation primarily for high net worth investors, today announced that the 2021 Noah Holdings Corporate Day will be held onsite in Shanghai, or online, on October 19, 2021. Attendees will be able to meet and discuss with the senior management team.

In order to assist us in our preparation for the event, please RSVP with name, title, company, contact number, online or onsite, by email to [email protected]. Event itinerary will be provided by the Company upon registration.

ABOUT NOAH HOLDINGS LIMITED

Noah Holdings Limited (NYSE: NOAH) is a leading and pioneer wealth management service provider in China offering comprehensive one-stop advisory services on global investment and asset allocation primarily for high net worth investors. In the first half of 2021, Noah distributed RMB52.1 billion (US$8.1 billion) of investment products. Through Gopher Asset Management, Noah had assets under management of RMB155.9 billion (US$24.1 billion) as of June 30, 2021.

Noah’s wealth management business primarily distributes private equity, private secondary, mutual fund and other products denominated in RMB and other currencies. Noah delivers customized financial solutions to clients through a network of 1,268 relationship managers in 81 cities in mainland China, and serves the international investment needs of its clients through offices in Hong Kong, Taiwan, United States and Singapore. The Company’s wealth management business had 397,235 registered clients as of June 30, 2021. As a leading multi-asset manager in China, Gopher Asset Management manages private equity, real estate, public securities, multi-strategy and other investments denominated in RMB and other currencies. The Company also provides other businesses.

For more information, please visit Noah at ir.noahgroup.com.

Noah Holdings Limited
Sonia Han, Melo Xi, Ryan Teng
Tel: +86-21-8035-8294

View original content:https://www.prnewswire.com/news-releases/noah-holdings-limited-to-hold-2021-corporate-day-on-october-19-2021-301377534.html

SOURCE Noah Holdings Limited

SÃO PAULO, Sept. 15, 2021 /PRNewswire/ — GOL Linhas Aéreas Inteligentes S.A. (NYSE: GOL and B3: GOLL4), (“GOL” or “Company”), Brazil’s largest airline, has agreed to expand its commercial cooperation with American Airlines Group Inc. (NASDAQ: AAL) (“American”) through an exclusive codeshare agreement (“Agreement”) for the next three years that will deepen the relationship between the two airlines. As part of the Agreement, GOL will receive an equity investment of US$200 million (R$1.05 billion) from American.

Through its exclusivity, the Agreement expands beyond the terms of the existing codeshare partnership between GOL and American, enhancing the travel opportunities for their passengers, the customer experience and the competitive position of GOL on routes connecting North and South America. In place since February 2020, the existing codeshare already represented the largest route network in the Americas, enabling the Company’s customers to travel seamlessly to more than 30 destinations in the U.S. The partnership flights currently operate in GOL’s hubs in São Paulo (GRU) and Rio de Janeiro (GIG), integrating 34 options of Brazilian and international routes, such as Montevideo, in Uruguay.

The completion of the Agreement and equity investment is subject to conditions, including the execution and delivery of definitive documentation and other customary closing conditions.

Exclusive Codeshare

“The exclusive codeshare agreement between two of the leading airlines in the Americas combines highly complementary route networks to offer customers a superior travel experience, due to the largest number of flights and destinations in North and South America,” said GOL CEO Paulo Kakinoff. “We believe that this will bolster GOL’s presence in international markets, accelerate our long-term growth, and maximize value for our shareholders. It adds to our confidence in the Company’s growth as the economy reopens and travel demand increases.”

GOL’s network services 63 destinations in Brazil as well as 140 international through codeshare agreements. The Company recently confirmed that Cancun (Mexico) and Punta Cana (Dominican Republic) will be its first international routes to reopen since the beginning of the Covid-19 pandemic. GOL will begin to operate flights on those routes by mid-November 2021.

Over the last 10 years, American has flown more than 14 million passengers between Brazil and the U.S., representing more than twice as much traffic as the next largest U.S. carrier. The combination of GOL’s leading network in Brazil and American’s leadership in the U.S.–Brazil market will maximize revenues through the increased connectivity and improved route options for Customers.

American Airlines President, Robert Isom, stated: “American has long been the leading U.S. carrier to South America and our exclusive partnership with GOL solidifies that leadership position. Our long-haul network marries seamlessly with GOL’s strong domestic network in Brazil and together, we will be able to offer customers flying to, through and from Brazil, access to the largest network with the lowest fares and the Americas’ biggest and best joint travel loyalty program.”

GOL’s Smiles and American’s AAdvantage loyalty programs will be partners in the largest frequent flyer program in the Americas with enhanced benefits coming in early 2022. This will include access for loyalty members to several benefits such as priority check-in, priority security, priority boarding, a larger checked baggage allowance, lounge access and preferred seats on both airlines. Customers may earn and redeem frequent flyer miles on both airlines.

The partnership between GOL and American also enables Customers to purchase connecting flights on both airlines using one reservation, in addition to creating a seamless ticketing, check-in, boarding and baggage check experience throughout an entire journey.

Equity Investment

American will invest US$200 million in 22.2 million newly issued preferred shares of GOL in a capital increase, for a 5.2% participation in the Company’s economic interest at a price of US$9.00 per preferred share (“PN” or “GOLL4”), equivalent to R$47.03 per PN as of 9/14/21 BRL/USD exchange rate. GOLL4’s closing price on 9/14/21 and average trading price during the second semester of 2019 were R$19.28 and R$35.68, respectively.

Richard Lark, GOL’s CFO added: “The investment represents recognition by a major U.S. airline carrier of the Company’s value as the largest airline in Brazil with the best product. Further, the investment, when combined with the R$2.7 billion of long-term capital raised in 2Q21, brings the total long-term capital raised to over R$3.7 billion in the last six months, including over R$2.0 billion of new equity capital. This additional liquidity further enhances GOL’s financial flexibility while minimizing dilution to shareholders.”

All holders of the Company’s preferred shares, including in the form of ADRs, will be able to exercise their preemptive rights to subscribe for a portion of the newly issued shares proportionate to their existing shareholdings.

The detailed terms and conditions of the capital increase are expected to be approved by the Board of Directors of GOL and disclosed in due course, including the final amount in Brazilian reais of the capital increase, issuance price, the record date, and the periods and procedures for the exercise of preemptive rights by the shareholders of the Company.

The equity investment described herein is subject to certain terms and conditions set forth in a letter of intent and a term sheet entered into on the date hereof between GOL and American. The right to proportionally subscribe for preferred shares according to the preemptive rights referred to in this release has not been registered with the U.S. Securities and Exchange Commission and will not be offered or extended absent registration or an applicable exemption from registration requirements.

Investor Relations  

[email protected]   
www.voegol.com.br/ir   
+55(11) 2128-4700

Media Relations 

Becky Nye, Montieth & Company 
[email protected]

About GOL Linhas Aéreas Inteligentes S.A.
GOL is Brazil’s largest airline, leader in the corporate and leisure segments. Since its founding in 2001, it has been the airline with the lowest unit cost in Latin America, which has enabled the democratization of air transportation. The Company has a strategic alliance with American Airlines and Air France-KLM, in addition to making available to Customers many codeshare and interline agreements, bringing more convenience and ease of connections to any place served by these partnerships. With the purpose of “Being First for Everyone”, GOL offers the best travel experience to its passengers, including: the largest inventory of seats and the most legroom; the most complete platform with internet, movies and live TV; and the best loyalty program, SMILES. In cargo transportation, GOLLOG delivers parcels to various regions in Brazil and abroad. The Company has a team of 15,000 highly qualified airline professionals focused on Safety, GOL’s number one value, and operates a standardized fleet of 127 Boeing 737 aircraft. GOL’s shares are traded on the NYSE (GOL) and the B3 (GOLL4). For further information, visit www.voegol.com.br/ir.

About American Airlines Group Inc.
American Airlines and American Eagle offer an average of nearly 6,700 flights per day to nearly 350 destinations in more than 50 countries. American has hubs in Charlotte, Chicago, Dallas/Fort Worth, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. American is a founding member of the oneworld® alliance, whose members serve more than 1,000 destinations with about 14,250 daily flights to over 150 countries. Shares of American Airlines Group Inc. trade on NASDAQ under the ticker symbol AAL. In 2015, its stock joined the S&P 500 index. American’s purpose is to care for people on life’s journey. Shares of American Airlines Group Inc. trade on Nasdaq under the ticker symbol AAL and the Company’s stock is included in the S&P 500. Learn more about what’s happening at American by visiting news.aa.com and connect with American on Twitter @AmericanAir and at Facebook.com/AmericanAirlines.

Disclaimer
The information contained in this press release has not been subject to any independent audit or review and contains “forward-looking” statements, estimates and projections that relate to future events, which are, by their nature, subject to significant risks and uncertainties. All statements other than statements of historical fact contained in this press release including, without limitation, those regarding GOL’s future financial position and results of operations, strategy, plans, objectives, goals and targets, future developments in the markets in which GOL operates or is seeking to operate, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “will”, “may”, “project”, “estimate”, “anticipate”, “predict”, “seek”, “should” or similar words or expressions, are forward-looking statements. The future events referred to in these forward-looking statements involve known and unknown risks, uncertainties, contingencies and other factors, many of which are beyond GOL’s control, that may cause actual results, performance or events to differ materially from those expressed or implied in these statements. These forward-looking statements are based on numerous assumptions regarding GOL’s present and future business strategies and the environment in which GOL will operate in the future and are not a guarantee of future performance. Such forward-looking statements speak only as at the date on which they are made. None of GOL or any of its affiliates, officers, directors, employees and agents undertakes any duty or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law. None of GOL or any of its affiliates, officers, directors, employees, professional advisors and agents make any representation, warranty or prediction that the results anticipated by such forward-looking statements will be achieved, and such forward-looking statements represent, in each case, only one of many possible scenarios and should not be viewed as the most likely or standard scenario. Although GOL believes that the estimates and projections in these forward-looking statements are reasonable, they may prove materially incorrect and actual results may materially differ. As a result, you should not rely on these forward-looking statements.

View original content:https://www.prnewswire.com/news-releases/gol-and-american-airlines-upgrade-to-exclusive-codeshare-agreement-301377531.html

SOURCE GOL Linhas Aéreas Inteligentes S.A.

NEW YORK, Sept. 15, 2021 /PRNewswire/ — Ambulnz, Inc., d/b/a DocGo, a leading provider of last-mile mobile health services and integrated medical mobility solutions that has entered into an agreement to merge with Motion Acquisition Corp. (Nasdaq: MOTN), today announced that it plans to hire 20 top-performing industry sales executives to further accelerate its strong growth and continue building on the proven success of its Mobile Health model.

After an exhaustive interview process with over 400 candidates, Mike Costa, DocGo’s EVP of Strategy, has already selected regional directors of growth strategy for DocGo’s markets in Florida, Arizona, Colorado, North and South Carolina, Texas, Rhode Island, and Connecticut.

“We have had significant interest in these roles and have met with hundreds of candidates thus far,” said Costa. “Everyone is keenly interested to learn more about how DocGo is disrupting the mobile health industry —especially with our high quality, convenient and affordable in-home services. And our recent Great Place To Work Certification^™ has certainly helped stoke candidates’ interest.”

Each new hire comes with a deep background in healthcare and proven success in building and leading the sales, implementation, and growth success from their prior organizations. All directors of growth strategy will be responsible for overseeing their region’s sales and go-to-market strategies, including coordinating and optimizing the company’s service offerings within each region.

“Attracting top talent is a priority as we grow our in-home care delivery model,” said DocGo President, Anthony Capone. “Our staff’s combined healthcare experience is essential to ensure our model continues to deliver high quality, low-cost healthcare as we continue to expand our services across our markets.”

DocGo leverages its unique set of assets and capabilities to partner with payers, physicians, health systems, employer groups, and others to deliver at-home and on-site care to reduce unnecessary emergency room visits, hospital stays, and readmissions. DocGo has experienced dramatic growth within the last year, entering 18 new geographic regions and nearly doubling its workforce to keep up with demand for its services.

About DocGo
DocGo is a leading provider of last-mile mobile care services and integrated medical mobility solutions. DocGo is disrupting the traditional four-wall healthcare system by providing care at the scale of humanity. DocGo’s innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. DocGo and Motion Acquisition Corp. (Nasdaq: MOTN) previously announced their definitive business combination agreement and recently filed a registration statement on Form S-4 with the SEC. Upon closing of the transaction, the combined company will operate under the DocGo name and will be listed on Nasdaq under the new ticker symbol “DCGO”. For more information, please visit www.docgo.com.

Forward-Looking Statements
Statements in this press release that are not historical in nature are forward-looking statements that, within the meaning of the federal securities laws including the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, involve known and unknown risks and uncertainties. Words such as “may”, “will”, “expect”, “intend”, “plan”, “believe”, “seek”, “could”, “estimate”, “judgment”, “targeting”, “should”, “anticipate”, “goal” and variations of these words and similar expressions, are intended to identify forward-looking statements. Readers are cautioned that actual results could differ materially from those implied by such forward-looking statements due to a variety of factors. Although we believe the expectations reflected in such forward-looking statements are based upon reasonable assumptions, we can give no assurances that our expectations will be attained. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/docgo-establishes-national-sales-team-to-drive-growth-301377075.html

SOURCE DocGo

Those achieving the most with cloud — “Continuum Competitors” — treat cloud as an operating model for innovation

TORONTO, Sept. 15, 2021 /CNW/ – A new global report from Accenture (NYSE: ACN) has identified a select group of organizations spanning several industries that treat cloud as a new operating model to continuously reinvent their businesses using innovative, multi-cloud capabilities — across public, private and edge — realize greater business value, well beyond cost savings.

Based on a survey of nearly 4,000 C-suite executives at both private- and public-sector organizations globally, including 200 Canadian executives, the report, titled “Ever-ready for Every Opportunity: How to Unleash Competitiveness on the Cloud Continuum,” explains why looking at cloud as a one-time migration to a static destination — essentially as a cheaper, more-efficient data centre — is limiting for most organizations, including those in Canada. In fact, a narrow focus on cost savings can actually put organizations at a competitive disadvantage compared to those using cloud more strategically across its many dynamic forms, including public, private and edge.

“While Canada is at the forefront of cloud adoption, many organizations today are deploying a mix of public, private and edge clouds, with little integration between them,” Jennifer Jackson, Technology and Cloud First Lead for Canada at Accenture. “This siloed approach limits organizations from reaping the greatest value from the cloud. However, our research found, a small percentage of Canadian organizations are viewing the cloud differently – as a continuum of technologies with diverse locations and types of ownership. They are using cloud as a launch pad for innovation and to develop new operating models, resulting in far greater value than just cost savings and operational efficiency.”

The report reveals that while Canadian organizations plan to migrate more than two-thirds of their workloads to cloud, on average, over the next three to five years, only half are using the full potential of cloud in its various forms to transform their day-to-day business operations, carry out knowledge work and modernize applications to meet business needs.

Accenture defines the organizations leading the way in cloud as “Continuum Competitors.” These organizations — about 12-15% of respondents globally — stand out by extending the experience they gained from public cloud to their private data centers and edge locations to transform daily business operations. As a result, they achieve substantial gains from their continued cloud engagement and outperform competitors. Continuum Competitors are also much better positioned to withstand future shocks, according to the research.

Continuum Competitors include organizations such as Carlsberg, for example.

 “A company’s future competitiveness hinges on choosing the right type of cloud for the right applications, and choosing cloud-based services across the continuum,” Jackson said. “Technologies like artificial intelligence, smart contact centres, edge computing, robotic computing and extended reality can give Canadian companies that competitive advantage. But all require a cloud-first approach, which allows for better customer experiences, smarter business processes and more sustainable products.”

Unlike organizations whose cloud efforts focus primarily on one-time migration to cloud for cost savings and efficiency, Continuum Competitors in Canada are:

• 1.6x more likely to see outcomes such as AI-augmented knowledge work;
• achieving 1.3x greater cost reduction than organizations focused mainly on data migration;
• targeting at least 1.3x better in financial and operational goals, such as increased customer value, lower operating costs, financial growth and flexibility, and scaling new innovations;
• 3.6x more likely to use the cloud for at least two sustainability goals, such as using green energy sources, designing for lower power consumption, and using servers more efficiently to reduce energy consumption.

By studying Continuum Competitors’ use of cloud, Accenture has identified four winning cloud approaches applicable to any organization:

1. Know where you want the continuum to take you. An organization must first develop a strategy with a vision that clearly states the core values and future aspirations, identifies competitive vulnerabilities and classifies capabilities relative to where the company is today and its future aspirations. They must develop these strategies by taking into account the constant evolution of cloud capabilities across the continuum.

2. Establish cloud practices to support and augment your technologies. Organizations need to couple technology adoption with practices that bring discipline and help change non-technology areas at the pace of computational improvements. Agility is the most critical mindset to being a Continuum Competitor; it infuses cloud-first apps, talent transformation, information technology experimentation and compute awareness, among other areas.  

3. Accelerate innovation to deliver exceptional experiences. Continuum Competitors prioritize their investments in one area: experience. They use a combination of human-centered design and cloud-based technologies such as edge computing to rethink experience to push it closer to where their customers, partners and employees engage. This is done by driving the experience mindset throughout the organization, including products and services, employee experience and delivery models.

4. Provide continuous strategic commitment. Leadership needs to establish business objectives, set appropriate risk levels and promote a culture of agility and growth. Organizations must also recognize the “all-hands” nature of the challenge: everyone across the organization needs to be informed of the cloud’s ever-improving potential and best practices.

Accenture’s “Ever-ready for Every Opportunity: How to Unleash Competitiveness on the Cloud Continuum” research arrives at a time when Canadian organizations have been forced by the pandemic to provide their customers with unique experiences and serve them in new and virtual ways. Prior global research from Accenture found that companies, including those Canada, that scaled technology innovation during COVID-19 are growing revenue approximately five times faster than lagging adopters of technology innovation.

About the Research 
In late 2020 and early 2021, Accenture surveyed nearly 4,000 C-suite executives, in both information technology (IT) and non-IT roles, across 25 countries and 16 industries. The research — which included interviews, case study research and economic modelling — focused on collecting data on adoption and scaling of technologies associated with cloud, each organization’s cloud journey, strategy, and goals, management practices around cloud, multiple measures of financial and operational performance, and the impact of cloud on innovation and sustainability outcomes.

About Accenture 
Accenture is a global professional services company with leading capabilities in digital, cloud and security. Combining unmatched experience and specialized skills across more than 40 industries, we offer Strategy and Consulting, Interactive, Technology and Operations services — all powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. Our 569,000 people deliver on the promise of technology and human ingenuity every day, serving clients in more than 120 countries. We embrace the power of change to create value and shared success for our clients, people, shareholders, partners and communities. Visit us at www.accenture.com.

Copyright © 2021 Accenture. All rights reserved. Accenture and its logo are trademarks of Accenture.

SOURCE Accenture

PALO ALTO, Calif., Sept. 15, 2021 /PRNewswire/ — BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company founded to discover, create, test and deliver meaningful medicines for patients with genetic diseases and cancers with clear genetic drivers, today announced that the United States Food and Drug Administration (FDA) granted Fast Track designation for the investigation of BBP-418 as a treatment option for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i). The FDA grants development programs Fast Track designation to help drive the development and expedite its review process for drugs being investigated to treat serious conditions and fill unmet medical needs. The FDA utilizes this program to provide patients access to important new drugs as early as possible. This is the fifth Fast Track designation for an investigational therapy that BridgeBio has received this year.

BridgeBio’s LGMD2i investigational therapy is one of the Company’s 14 programs that are in the clinic or commercial setting for patients living with genetic diseases and genetically-driven cancers.

BridgeBio’s first wave of programs are the now-approved drugs for Molybdenum Cofactor Deficiency (MoCD) Type A and previously-treated locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement. The second wave of programs includes the Company’s four major near-term catalysts for its product candidates for the treatment of transthyretin (TTR) amyloidosis (ATTR), achondroplasia, congenital adrenal hyperplasia (CAH) and autosomal dominant hypocalcemia type 1 (ADH1).

LGMD2i represents one of the leading programs in BridgeBio’s ongoing third wave in development, which includes a variety of programs in the cancer and mendelian space already in the clinic.

With approximately 7,000 patients with potentially treatable mutations, LGMD2i is an inherited recessive muscular dystrophy caused by mutation of fukutin-related protein (FKRP). FKRP is a critical enzyme that adds a specific sugar molecule to a muscle cell structural protein called alpha-dystroglycan (αDG). Due to defective FKRP enzyme function, muscle cells of patients affected by LGMD2i lack a robust cushioning system that is provided by fully glycosylated αDG proteins. Pediatric and adult patients with LGMD2i most commonly present with upper and lower extremity (“limb”) and thoracic (“girdle”) dysfunction (“limb-girdle” pattern of weakness), and without treatment often develop additional severe clinical manifestations, including loss of independent ambulation, severe breathing issues which can require mechanical ventilation, cardiomyopathy and premature death.

“As of now, there are no approved treatment options for people born with Limb-girdle Muscular Dystrophy Type 2i. People living with this disease can lose their ability to perform routine daily activities, and ultimately may lose the ability to walk, need ventilatory support or face the risk of heart failure,” said Douglas Sproule, M.D., M.Sc., chief medical officer of ML Bio Solutions, Inc., the BridgeBio company developing BBP-418. “We are grateful the FDA has granted our program Fast Track designation based on the potential of our investigational therapy to treat this very serious condition. We are hopeful the designation will allow us to address this unmet medical need by allowing us to potentially deliver our medicine to patients more quickly.”

BBP-418 is being investigated as a treatment for LGMD2i. The investigational therapy is designed to overcome the enzymatic limitation of the defective FKRP enzyme by supplementing endogenous sugar molecules to glycosylate αDG and to improve muscle cell integrities, resulting in improved muscle strength and function for patients. Clinical trials to verify the safety and efficacy of BBP-418 are ongoing.

BBP-418 has received Orphan Drug Designation for the treatment of LGMD2i from the FDA and for LGMD from the European Medicines Agency. BridgeBio is currently advancing its Phase 2 clinical trial in subjects with a genetically confirmed diagnosis of LGMD2i. If the development program is successful, BBP-418 could be the first approved therapy for the treatment of patients with LGMD2i.

About Limb-girdle Muscular Dystrophy Type 2i
LGMD2i is a monogenic autosomal recessive disease caused by partial loss of function mutations in the FKRP gene, and these FKRP mutations impair glycosylation of α-DG, a protein associated with stabilizing muscle cells.  LGMD2i is a disease that has pediatric symptomatic onset with most individuals developing manifestations of disease between 5 and 18 years of age. Clinical manifestations typically present as a skeletal myopathy affecting the lower and then upper limbs, which is commonly later accompanied by respiratory muscle and cardiac muscle involvement.  Patients who harbor a homozygous genotype typically develop disease manifestations during late childhood with progression to loss of independent ambulation (25%), assisted ventilation (5%), and cardiomyopathy (10%) in adulthood. Cardiomyopathy is progressive, with an annual loss of 0.4% of left ventricular ejection fraction (LVEF). Patients with heterozygous genotypes have an earlier childhood onset with a more severe clinical course, rapid loss of mobility by 20 years of age, more frequent cardiac involvement (25%), and eventual respiratory failure by 30 years of age in nearly all cases.

About BridgeBio Pharma, Inc.
BridgeBio Pharma Inc. (BridgeBio) is a biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio’s pipeline of over 30 development programs ranges from early science to advanced clinical trials, and its commercial organization is focused on delivering the company’s first two approved therapies. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers, and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn and Twitter.

BridgeBio Pharma, Inc. Forward-Looking Statements
This press release contains forward-looking statements. Statements we make in this press release may include statements that are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions.  We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Exchange Act and are making this statement for purposes of complying with those safe harbor provisions.  These forward-looking statements, including statements relating to the timing and success of ML Bio Solutions’ clinical trials of BBP-418 for the treatment of LGMD2i, expectations, plans and prospects regarding ML Bio Solutions’ regulatory approval process for BBP-418, the ability of BBP-418 to treat LGMD2i in humans, the potential for BBP-418 to be the first approved therapy for the treatment of LGMD2i and the timing and success of BridgeBio’s clinical trials and development pipeline, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved.  Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a number of risks, uncertainties and assumptions, including, but not limited to, ML Bio Solutions’ ability to continue and complete its clinical trials of BBP-418 for the treatment of LDMD2i, past data from preclinical studies not being indicative of future data from clinical trials, ML Bio Solutions’ ability to advance BBP-418 in clinical development according to its plans, the ability of BBP-418 to be the first approved therapy for the treatment of patients with LGMD2i, BridgeBio’s ability to advance its clinical trials and development pipeline, the success of BridgeBio’s approved drugs, as well as those risks set forth in the Risk Factors section of BridgeBio Pharma’s Annual Report on Form 10-K for the year ended December 31, 2020, and BridgeBio Pharma’s other SEC filings. Moreover, ML BioSolutions operates in a very competitive and rapidly changing environment in which new risks emerge from time to time. Except as required by applicable law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

BridgeBio Media Contact: 
Grace Rauh
[email protected]
(917) 232-5478

BridgeBio Investor Contact:

Katherine Yau

[email protected]

(516) 554-5989

View original content to download multimedia:https://www.prnewswire.com/news-releases/bridgebio-pharma-receives-fda-fast-track-designation-for-investigational-therapy-for-the-treatment-of-limb-girdle-muscular-dystrophy-type-2i-lgmd2i-301377058.html

SOURCE BridgeBio

MONTREAL
, Sept. 15, 2021/PRNewswire/ – Alithya Group inc. (TSX: ALYA) (NASDAQ: ALYA) (“Alithya” or the “Company”), a leader in strategy and digital transformation employing more than 3,300 highly qualified professionals and offering enterprise cloud solutions across Canada, the U.S. and Europe, is pleased to announce today that the Toronto Stock Exchange (the “TSX”) has accepted a notice filed by Alithya of its intention to commence a normal course issuer bid (“NCIB”).

Under the NCIB, the Company will be allowed to purchase for cancellation on the open market through the facilities of the TSX and NASDAQ, or through alternative trading systems, if eligible, or outside the facilities of the TSX pursuant to exemption orders issued by securities regulatory authorities, up to
5,462,572
Class A subordinate voting shares (“Class A Shares”), representing 10% of the Company’s public float as of the close of markets on September 8, 2021
. The amount of purchases on any given day will not exceed 22,259 Class A Shares, which represents 25% of the average daily trading volume on the TSX for the six-month ended August 31, 2021, being 89,038
Class A



Shares, calculated in accordance with the rules of the TSX. All Class A Shares purchased under the NCIB will be cancelled.

Purchases under the NCIB may commence on September
20
, 2021 and will end on the earlier of September 
19,
2022 and the date on which the Company will have acquired the maximum number of Class A Shares allowable under the NCIB or otherwise decided not to make any further purchases. All purchases of Class A Shares will be made by means of open market transactions at their market price at the time of acquisition, plus brokerage fees, except for purchases that could be effected pursuant to exemption orders issued by securities regulatory authorities, which would be at a discount to the prevailing market price as per the terms of the order.

The decisions regarding the timing and size of purchases under the
NCIB
are subject to management’s discretion and are based on a variety of factors, including market conditions. The Company believes that the purchase of Class A Shares from time to time can be undertaken at prices that do not fully reflect their value. The Company believes that, in such circumstances, the repurchase of such Class A Shares represents an appropriate use of the Company’s available funds to support shareholder value.

The Company entered into an automatic share purchase plan (“ASPP”) with a designated broker in connection with its NCIB. The ASPP will allow for the purchase for cancellation of Class A Shares, subject to certain trading parameters, by its designated broker during times when Alithya would ordinarily not be active in the market due to applicable regulatory restrictions or self-imposed blackout periods. Outside of these periods, the Class A Shares will be repurchased by Alithya at its discretion under the NCIB.

Alithya has not repurchased any Class A Shares under a NCIB in the last twelve months.

Forward-Looking Statements

This press release contains statements that may constitute “forward-looking information” within the meaning of applicable Canadian securities laws and “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other applicable U.S. safe harbours (collectively “forward-looking statements”). Statements that do not exclusively relate to historical facts, as well as statements relating to management’s expectations regarding the future growth, results of operations, performance and business prospects of Alithya, and other information related to Alithya’s business strategy and future plans or which refer to the characterizations of future events or circumstances represent forward-looking statements. Such statements often contain the words “anticipates,” “expects,” “intends,” “plans,” “predicts,” “believes,” “seeks,” “estimates,” “could,” “would,” “will,” “may,” “can,” “continue,” “potential,” “should,” “project,” “target,” and similar expressions and variations thereof, although not all forward-looking statements contain these identifying words.

Forward-looking statements in this press release include, among other things, information or statements relating to potential future purchases by Alithya of its Class A Shares pursuant to the NCIB and the ASPP.

Forward-looking statements are presented for the sole purpose of assisting investors and others in understanding Alithya’s objectives, strategies and business outlook as well as its anticipated operating environment and may not be appropriate for other purposes. Although management believes the expectations reflected in Alithya’s forward-looking statements were reasonable as at the date they were made, forward-looking statements are based on the opinions, assumptions and estimates of management and, as such, are subject to a variety of risks and uncertainties and other factors, many of which are beyond Alithya’s control, and which could cause actual events or results to differ materially from those expressed or implied in such statements. Such risks and uncertainties include but are not limited to those discussed in the section titled “Risks and Uncertainties” of Alithya’s annual and interim Management’s Discussion and Analysis and other materials made public, including documents filed with Canadian and U.S. securities regulatory authorities from time to time and which are available on SEDAR at www.sedar.com and EDGAR at www.sec.gov. Additional risks and uncertainties not currently known to Alithya or that Alithya currently deems to be immaterial could also have a material adverse effect on its financial position, financial performance, cash flows, business or reputation.

There can be no assurance that Alithya will repurchase all or any of the numbers of Class A Shares referred to in this press release that are subject to the NCIB.

Forward-looking statements contained in this press release are qualified by these cautionary statements and are made only as of the date of this press release. Alithya expressly disclaims any obligation to update or alter forward-looking statements, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by applicable law. Investors are cautioned not to place undue reliance on forward-looking statements since actual results may vary materially from them.

About Alithya

Alithya is a North American leader in strategy and digital transformation. The Company employs more than 3,300 professionals in Canada, the United States, and Europe. Alithya’s integrated offer is based on four pillars of expertise: business strategies, enterprise cloud solutions, application services, and data and analytics. Alithya deploys leading-edge solutions, services, and skills to develop tools designed to meet the unique needs of customers in a variety of sectors, including financial services, manufacturing, renewable energy, telecommunications, transport and logistics, professional services, healthcare and government. To learn more about Alithya, visit www.alithya.com.

View original content:https://www.prnewswire.com/news-releases/alithya-announces-normal-course-issuer-bid-301376475.html

SOURCE Alithya

CRANBURY, N.J., Sept. 15, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor systems, today announced a featured speaker presentation and two poster presentations at the upcoming TIDES USA hybrid conference in Boston, Massachusetts on September 20-23, 2021.

“We are excited to continue our partnership with TIDES to continue informing the peptide world about our robust pipeline of melanocortin agonists as possible treatments for inflammatory conditions,” said Carl Spana, Ph.D., President and Chief Executive Officer of Palatin.  “The gut, as well as the eye, offer multiple unique opportunities for melanocortins to promote resolution of inflammation.”

Dr. Spana is a featured speaker and will discuss the Company’s broad expertise in melanocortin peptides, including its development programs for inflammation. The poster presentations by John Dodd, Ph.D., Senior Vice President of Preclinical Research, demonstrates the possible utility of melanocortins in inflammation, and presents animal disease model data specific to colon inflammation. 

TIDES USA is conducting a hybrid live and digital event with presentations across multiple drug development functional groups from development through commercialization for oligos, peptides, mRNA and genome editing products.

Presentation and Poster details are:

• Featured Speaker presentation entitled “Development of Melanocortin-based Peptide Therapeutics: Vyleesi (FDA Approved) and Next Generation of Novel Peptides That Resolve Inflammation” will be presented on September 21, 2021, by Dr. Spana.
• Two poster presentations by Dr. Dodd, provide an overview of the exciting potential utility of melanocortin agonists for the treatment of inflammatory diseases, with the second poster providing specific data in an inflammatory disease rat model. The posters are titled:
• Probing the Role of the Melanocortin Receptor Agonists in Experimental Immune-Mediated Diseases
• Effect of the Melanocortin Receptor Agonist PL8177 on DSS-Induced Colitis in Rats and a Toxicologic Assessment of PL8177 in Beagle Dogs

Both poster presentations will be available on the TIDES USA conference website for registered attendees and will be available on Palatin’s website today at www.palatin.com.

About Melanocortins and Inflammation

The melanocortin receptor (“MCr”) system has effects on food intake, metabolism, sexual function, inflammation, and immune system responses. There are five melanocortin receptors, MC1r through MC5r. Modulation of these receptors, through use of receptor-specific agonists, which activate receptor function, or receptor-specific antagonists, which block receptor function, can have significant pharmacological effects.

Many tissues and immune cells located in the eye express melanocortin receptors, empowering our opportunity to directly activate natural pathways to resolve disease inflammation.

About Palatin

Palatin is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems, with targeted, receptor-specific product candidates for the treatment of diseases with significant unmet medical need and commercial potential. Palatin’s strategy is to develop products and then form marketing collaborations with industry leaders to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin’s website at www.palatin.com.

Forward-looking Statements

Statements in this press release that are not historical facts, including statements about future expectations of Palatin, such as statements about clinical trial plans and potential results for peptides under development to resolve inflammation and inflammatory diseases, are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. Palatin intends that such forward-looking statements be subject to the safe harbors created thereby. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause Palatin’s actual results to be materially different from its historical results or from any results expressed or implied by such forward-looking statements. Palatin’s actual results may differ materially from those discussed in the forward-looking statements for reasons including, but not limited to, results of clinical trials, regulatory actions by the FDA and other regulatory and the need for regulatory approvals, Palatin’s ability to fund development of its technology and establish and successfully complete clinical trials, the length of time and cost required to complete clinical trials and submit applications for regulatory approvals, products developed by competing pharmaceutical, biopharmaceutical and biotechnology companies, commercial acceptance of Palatin’s products, and other factors discussed in Palatin’s periodic filings with the Securities and Exchange Commission. Palatin is not responsible for updating for events that occur after the date of this press release.

View original content to download multimedia:https://www.prnewswire.com/news-releases/palatin-to-present-peptides-platform-at-the-tides-usa-conference-301377246.html

SOURCE Palatin Technologies, Inc.

CHICAGO, Sept. 15, 2021 /PRNewswire/ — Donnelley Financial Solutions, Inc. (NYSE: DFIN), (the “Company”) announced today that it has delivered a redemption notice to Wells Fargo Bank, National Association to redeem on October 15, 2021, all of the outstanding $233,001,000 aggregate principal amount of 8.250% Senior Notes due 2024 issued by the Company (the “Notes”). The redemption price for the Notes will be 102.063% of outstanding principal amount of the Notes, plus accrued and unpaid interest, if any, to, but not including the Redemption Date (the “Redemption Price”).  Capitalized terms used herein, and not otherwise defined, have the meanings assigned to them in the Indenture, dated as of September 30, 2016, between the Company and Wells Fargo Bank, National Association, as trustee.

The Notes are held only in book-entry form through The Depository Trust Company (“DTC”).  DTC will redeem the Notes in accordance with its procedures and notify holders.  Holders of the Notes need not take any action to receive payment of the redemption price.

The Company intends to fund the redemption with a $200 million draw on the Delayed Draw Term A Loan Facility available under its Credit Agreement and cash on its balance sheet.

“At current interest rates, the expected annualized interest savings on the refinancing is approximately $14 million,” said David A. Gardella, DFIN’s executive vice president and chief financial officer.  “In addition, while this structure subjects our remaining debt to interest rate movements, a rising rate environment would reduce the net liability related to our defined benefit pension plans.  Such a reduction would decrease the amount of required annual contributions, and potentially allow us to annuitize the plans at no cost, eliminating altogether our net pension liability and the related future contributions.”

About DFIN

DFIN is a leading global risk and compliance solutions company. We provide domain expertise, enterprise software and data analytics for every stage of our clients’ business and investment lifecycles. Markets fluctuate, regulations evolve, technology advances, and through it all, DFIN delivers confidence with the right solutions in moments that matter. Learn about DFIN’s end-to-end risk and compliance solutions online at DFINsolutions.com or you can also follow us on Twitter @DFINSolutions or on LinkedIn.

Use of Forward-Looking Statements

This news release includes certain “forward-looking statements” within the meaning of, and subject to the safe harbor created by, Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the business, strategy and plans of DFIN, its expectations relating to future financial condition and performance, and its ability to annuitize its pension plans. Statements that are not historical facts, including statements about DFIN management’s beliefs and expectations, are forward-looking statements. Words such as “believes,” “anticipates,” “estimates,” “expects,” “intends,” “aims,” “potential,” “will,” “would,” “could,” “considered,” “likely,” “estimate” and variations of these words and similar future or conditional expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. While DFIN believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond DFIN’s control. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend upon future circumstances that may or may not occur. Actual results may differ materially from DFIN’s current expectations depending upon a number of factors affecting the business and risks associated with the performance of the business. These factors include such risks and uncertainties detailed in DFIN periodic public filings with the SEC, including but not limited to those discussed under “Risk Factors” in DFIN’s Form 10-K for the fiscal year ended December 31, 2020, those discussed under “Cautionary Statement” in DFIN’s quarterly Form 10-Q filings, and in other investor communications of DFIN’s from time to time. DFIN does not undertake to and specifically declines any obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect future events or circumstances after the date of such statement or to reflect the occurrence of anticipated or unanticipated events.

View original content to download multimedia:https://www.prnewswire.com/news-releases/donnelley-financial-solutions-announces-redemption-of-senior-notes-301377094.html

SOURCE Donnelley Financial Solutions

COLUMBUS, Ohio, Sept. 15, 2021 /PRNewswire/ — Alliance Data Systems Corporation (NYSE: ADS), a leading provider of data-driven marketing, loyalty and payment solutions, provided an update on its Card Services segment. The following tables present the Company’s net charge-offs and delinquency rate for the periods indicated.

 

About Alliance Data

Alliance Data
^® (NYSE: ADS) is a leading provider of data-driven marketing, loyalty and payment solutions serving large, consumer-based industries. The Company creates and deploys customized solutions that measurably change consumer behavior while driving business growth and profitability for some of today’s most recognizable brands. Alliance Data helps its partners create and increase customer loyalty across multiple touch points using traditional, digital, mobile and emerging technologies. Headquartered in Columbus, Ohio, Alliance Data is an S&P MidCap 400 company that consists of businesses that together employ approximately 8,000 associates at more than 45 locations worldwide.

Alliance Data’s Card Services business is a comprehensive provider of market-leading private label, co-brand, general purpose and business credit card programs, digital payments, including Bread^®, and Comenity-branded financial services. LoyaltyOne^® owns and operates the AIR MILES^® Reward Program, Canada’s most recognized loyalty program, and Netherlands-based BrandLoyalty, a global provider of tailor-made loyalty programs for grocers. More information about Alliance Data can be found at www.AllianceData.com.

Follow Alliance Data on Twitter,Facebook, LinkedIn, Instagram and YouTube.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements give our expectations or forecasts of future events and can generally be identified by the use of words such as “believe,” “expect,” “anticipate,” “estimate,” “intend,” “project,” “plan,” “likely,” “may,” “should” or other words or phrases of similar import. Similarly, statements that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding, and the guidance we give with respect to, our anticipated operating or financial results, initiation or completion of strategic initiatives including the proposed spinoff of our LoyaltyOne segment, future dividend declarations, and future economic conditions, including, but not limited to, fluctuation in currency exchange rates, market conditions and COVID-19 impacts related to relief measures for impacted borrowers and depositors, labor shortages due to quarantine, reduction in demand from clients, supply chain disruption for our reward suppliers and disruptions in the airline or travel industries.

We believe that our expectations are based on reasonable assumptions. Forward-looking statements, however, are subject to a number of risks and uncertainties that could cause actual results to differ materially from the projections, anticipated results or other expectations expressed in this release, and no assurances can be given that our expectations will prove to have been correct. These risks and uncertainties include, but are not limited to, factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the most recently ended fiscal year, which may be updated in Item 1A of, or elsewhere in, our Quarterly Reports on Form 10-Q filed for periods subsequent to such Form 10-K. Our forward-looking statements speak only as of the date made, and we undertake no obligation, other than as required by applicable law, to update or revise any forward-looking statements, whether as a result of new information, subsequent events, anticipated or unanticipated circumstances or otherwise.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alliance-data-provides-card-services-performance-update-for-august-2021-301377272.html

SOURCE Alliance Data Systems Corporation